Description
Pharmaceutical CAS 76547-98-3 Lisinopril Dihydrate For Blood Pressure Medication
Description
| Product Name: | Lisinopril Dihydrate | CAS No: | 83915-83-7 |
|---|---|---|---|
| MF: | C21H31N3O5 | MW: | 405.49 |
| Purity: | 98% Min | Shelf Life: | 2 Years |
| Application: | Pharmaceutical API | Storage: | Cool And Dry Place |
| Package: | 25KG/drum | ||
| High Light: |
Pharmaceutical Lisinopril Dihydrate, Lisinopril Dihydrate For Blood Pressure Medication, CAS 76547-98-3 Pharmaceutical Powder |
||
Lisinopril Dihydrate Raw Powder Treatment Blood Pressure Medication CAS 76547-98-3
About this product
Lisinopril is a third-generation angiotensin-converting enzyme inhibitor and a lysine derivative of enalapril. It was marketed in the United States in 1987 for the treatment of hypertension and is a first-line antihypertensive drug . The pharmacological action characteristics are similar to Enalapril (Enalapril), with strong angiotensin-converting enzyme inhibitory effect, quick onset and long action time, just take the medicine once a day. The inhibitory effect on ACE is 6 to 8 times that of captopril and 1 to 3 times that of benazepril. It can significantly reduce the total peripheral resistance and blood pressure Chemicalbook, but it is not accompanied by reflex tachycardia. Lisinopril can reduce pulmonary wedge pressure, increase cardiac output, increase left ventricular ejection fraction, and improve heart function in patients with heart failure. It can increase renal blood flow, reduce renal vascular resistance, and increase glomerular filtration rate. It can be used alone or in combination with other drugs to treat various degrees of hypertension and renal hypertension for which other antihypertensive drugs are ineffective. It can also be used alone or in combination with digitalis and diuretics to treat congestive heart failure. It can also be used as an adjuvant treatment for patients with stable hemodynamics after acute myocardial infarction.
Function
Angiotensin Converting Enzyme Inhibitor (ACE-I), a lysine derivative of Enalapril, is the third non-sulfhydryl group in the world to be marketed. ACE-I. Long-acting, once a day, and the dosage is only 1/20 of captopril, 1/4 of enalapril, oral bioavailability is better. The curative effect is remarkable. For moderate and severe patients, the Chemicalbook should be better than captopril and enalapril. It has no direct effect on the heart, does not cause arrhythmia, has no central effect, and has no adverse reactions such as blood pressure rebound. It can be used for diseases accompanied by diabetes, asthma, peripheral vascular disease, psychosis and congestive heart failure, and for other diseases Patients with hypertension who are contraindicated in the treatment of drugs. It is effective for short-term and long-term congestive heart failure.
Related products
| Product Name | CAS No. | Product Name | CAS No. |
| Lufenuron | 103055-07-8 | Toltrazuril | 69004-03-1 |
| Nitenpyram | 120738-89-8 | Praziquantel/Biltricide | 55268-74-1 |
| Fenbendazole | 43210-67-9 | Tetramisole Hcl | 5086-74-8 |
| Levamisole | 14769-73-4 | Ponazuril | 9004-4-2 |
| Diclazuril | 101831-37-2 | Florfenicol | 73231-34-2 |
| Ivermectin | 70288-86-7 | Enrofloxacin Hcl | 112732-17-9 |
| Albendazole | 54965-21-8 | Mebendazole | 31431-39-7 |
Warnings
All products are exported for Lab & Research use in legal and Non-patented area only. Products may not be used in human or animals. Individuals are fully responsible for all consequences arising therefrom.
